Celltrion has credited continued growth for its leading biosimilars, including increased uptake of Truxima (rituximab) in the US and the expansion of indications for its subcutaneous Remsima SC (infliximab) in Europe, for a significant rise in sales and profits in 2020.
Moreover, after recently receiving a pan-European marketing authorization for its Yuflyma (adalimumab) high-concentration biosimilar rival to Humira, Celltrion said that it expected a continued expansion of its portfolio to be